AllCells® - Advance your cell and gene therapy program with high-quality human cellular starting materials and integrated analytics - all in one place.
AllCells®, a division of Discovery Life Sciences, has been providing high-quality primary cell products and integrated services to support the cell and gene therapy (CGT) industry since 1998. AllCells' RUO and GMP products come with industry-leading viability for optimal consistency and reproducibility.
With over three decades of combined experience serving the CGT market and an unmatched global network of well-characterized, highly engaged recallable donors, AllCells provides a revolutionary set of scalable, end-to-end CGT solutions.
Their scientific experts optimize projects with an innovative, collaborative, flexible, and client-centric approach, providing cell isolation, cell culture, and immunophenotypic and functional profiling services adjacent to donor clinics to help define process analytics and inform decision-making.
AllCells' leukopaks are enriched leukapheresis products collected from healthy and consenting donors using the Spectra Optia® Apheresis System following an IRB-approved protocol. Their leukopaks typically contain up to 50% T cells, 20% monocytes, 10% B cells, 10% NK cells, 3% granulocytes, and 3% hematocrit.
Leukapheresis results in high yields of single-donor mononuclear cells (MNCs) compared to venipuncture collection or buffy coat isolation. AllCells' leukopaks allow for scalability and reproducibility of experiments by limiting the impact of donor-to-donor variability.
AllCells offers made-to-stock (MTS) cryopreserved leukopaks for project flexibility as well as made-to-order (MTO) leukopaks engineered to meet unique project needs.
AllCells is the industry leader in supplying mobilized Leukopaks with the shortest lead time on the market. Mobilized Leukopaks are apheresis products collected from healthy donors treated with FDA-approved drugs to stimulate the migration of CD34+ hematopoietic stem and progenitor cells (HSPCs) from the bone marrow niche into the circulation. Mobilized peripheral blood, enriched in single-donor CD34+ HSPCs is collected through leukapheresis using the Spectra Optia® Apheresis System's continuous flow centrifugal technology. The ease of collection and high yield of single-donor CD34+ cells is a major advantage to researchers to gain experimental consistency and scalability.
AllCells has six different mobilization regimens available using G-CSF (Neupogen®), plerixafor (Mozobil®), or a combination of the two drugs as well as CD34+ cells isolated from mobilized Leukopaks.
Bone marrow is an excellent source of CD34+ hematopoietic stem and progenitor cells (HSPCs) and mesenchymal stem cells. It is the primary site of hematopoiesis in adults, the process of mature blood cell formation from HSPCs to maintain blood homeostasis.
AllCells' bone marrow products are collected by qualified clinicians from the posterior iliac crest of healthy and consenting donors following IRB-approved protocols. Bone marrow is available in fresh, cryopreserved, or frozen, and in different formats.
Umbilical Cord Blood is a rich source of primitive CD34+ hematopoietic stem and progenitor cells reported to be more naive with a higher proliferative, engraftment and multipotent potential than those isolated from adult bone marrow. Because of these attributes, cord blood can be a great tool for applications where bypassing HLA mismatch is required. AllCells offers cryopreserved cord blood CD34+ isolated cells from a single umbilical cord or from multiple cord blood units for mixed donor products.
Isolated Cell Products
AllCells offers bulk cell isolations of important cell types from single-donor leukapheresis and bone marrow material - standard and sequential immunomagnetic separation protocols are available. Obtain large quantities of quality-controlled cells including CD34+ HSPCs, lymphocyte populations (T cells, B cells, NK cells, and monocytes), and PBMCs for a variety of research and biomedical applications.
Obtaining bulk quantities of highly pure and viable isolated cells from a qualified vendor offers researchers the opportunity to bank cells to support experimental consistency and comparability, and streamlines laboratory workflows.
AllCells' proven capabilities help clients navigate and streamline the complex journey from product development to commercialization. When clinical applications and increased regulatory compliance are required, AllCells' GMP, clinical-grade products are offered to meet the later stages of product development.
Partnering with AllCells for RUO and GMP products to span the entire workflow mitigates timeline and cost delays that could arise from having to revalidate source material and suppliers. This also provides the flexibility and agility to bilaterally transition between pre-clinical and clinical phases to address the dynamic nature of cell therapy product development.